Akari Therapeutics announces preclinical data on PH1

Akari Therapeutics (AKTX) announced key preclinical data demonstrating the potential of its novel antibody drug conjugate, ADC, spliceosome modulating payload, PH1, for the treatment of tumors fueled by alternative splicing-drivers, such as the Androgen Receptor splice variant 7, AR-V7, in prostate cancer. Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics commented, “We believe these compelling preclinical data support the rationale for Akari to develop a novel ADC with our PH1 spliceosome-modulating payload targeting prostate cancer either alone or in partnership with potential partners. Our goal is to develop the first ADC therapeutic in prostate cancer, either as a first-line combination therapy with ARPIs or a second-line therapy post ARPI failures in tumors driven by AR-V7. We are excited to continue to advance this novel spliceosome modulating payload to drive robust anti-cancer biological mechanisms to treat difficult alternative splicing-driven tumors, for which there are currently no effective treatment options today.”